Table 1.
Demographic characteristics of patients with systemic autoimmune rheumatic diseases (ARDs) and the healthy group.
| Baseline characteristics | Total N = 60(%) | SARDs n = 30 (%) | Healthy group n = 30 (%) | P value |
|---|---|---|---|---|
| Female | 52 (86.7) | 26 (86.7) | 26 (86.7) | 1 |
| Median age, y (IQR) | 38.5 (25.5, 50) | 41.5 (31.5,51.8) | 35 (23,48.8) | 0.181 |
| Time to analysis, days (IQR) | 32 (29,34) | 32 (29,34) | 32 (29,35) | 0.759 |
| SARD n = 30 | ||||
| SLE | 15 (50.0) | |||
| RA | 10 (33.3) | |||
| Othera | 5 (16.7) | |||
| GC use | 24 (80) | |||
| GC dose, mean (SD) | 6.7 (2.8) | |||
| Immunosuppressive drug | ||||
| Azathioprine | 13 (43.3) | |||
| Methotrexate | 12 (40) | |||
| Mycophenolate | 5 (16.7) | |||
| Leflunomide | 3 (10) | |||
| Cyclophosphamide | 1 (3.3) | |||
| Multiple DMARDs | 5 (16.7) | |||
SARDs systemic autoimmune rheumatic diseases, DMARDs disease-modifying antirheumatic drugs, GC glucocorticoids, RA rheumatoid arthritis, SLE systemic lupus erythematosus.
an = 2 psoriatic arthritis, n = 1 systemic vasculitis, n = 1 systemic sclerosis, n = 1 dermatomyositis.